1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
SOHO 2026 Annual Meeting
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
CML - 797
Comparison of the Incidence of Cardiovascular Adverse Events in Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors With Representatives of the General Population
Poster Presenter
Authors
Part of Topic
Chronic Myeloid Leukemia (CML)
Comparison of the incidence of cardiovascular adverse events in patients with chronic myeloid leukaemia receiving tyrosine kinase inhibitors with representatives of the general population.
Intro
Some tyrosine kinase inhibitors (TKI) used in chronic myeloid leukemia (CML) treatment have cardiovascular toxicity, which may be a contraindication for their use in patients with cardiovascular (CV) risk factors. In patients with CV risk factors or a history of CV disease, it is difficult to determine the contribution of TKI or premorbid background to their CV outcomes.
Aim
To compare the frequency and profile of cardiovascular outcomes in patients with CML receiving TKI with those in the general population with similar anthropometric parameters, CV risk factors, and history of CV disease.
Materials and methods
The study included patients with CML in the chronic phase – CML-group, and representatives of the general population (included in the epidemiological study ESSE-RF) as the control group. Members of the CML group and the control group were comparable in terms of gender, age (+-5 years), body mass index (BMI) (+-3 kg/m2), history of CV disease or diabetes mellitus (DM), and statin use.
CML-group included 112 patients (women - 61%), median age was 49.5 years. The mean low-density lipoprotein (LDL) level was 2.58 mmol/L. 22 patients (20%) were taking statins.
Control group included 224 people, median age was 49 years. The LDL level was 3.46 mmol/L. 44 people (20%) were taking statins.
Results
CV outcomes were analyzed for the CML group and the control group with a median follow-up of 80 months (CML group) and 72 months (control group).
CV adverse effects (CVAE) developed in 9 CML patients (8%): stable angina pectoris – 1, peripheral arterial atherosclerosis– 5, acute stroke – 3. The median time from the start of TKI, on which CVAE developed, to CVAE was 45 months.
CVAE in the control group: MI in 4 people (2%), stroke in 2 people (1%), while 1 person developing stroke and MI sequentially. Median time to CVAE was 50.9 months
Conclusion
When comparing the group of CML patients with the control group, assuming comparable anthropometric characteristics and CV history, a significantly higher number of CVAE was observed in patients with CML.